KINAXO lends technologies to AstraZeneca’s oncology programs
MARTINSRIED—KINAXO Biotechnologies GmbH recently entered into a collaboration with AstraZeneca under which KINAXO will apply its technology platform to support one of AstraZeneca's oncology programs. KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. According to the companies, since protein modifications play pivotal roles in many cellular processes, such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets. Financial details of the agreement were not disclosed.
"Post-translational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action," says Dr. Henrik Daub, KINAXO's chief technology officer. "This collaboration further strengthens KINAXO's position as a preferred technology partner for global pharmaceutical companies."